Docetaxel: 7 agencies, 2003–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 17.3 years separate the first record, 9 May 2003 at SMC (Scotland), from the most recent, 24 Sep 2020 at PHARMAC (New Zealand).
PHARMAC (New Zealand) changed its position: not recommended on 1 Nov 2004, recommended by 24 Sep 2020, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for docetaxel, 1 submission was never made and 5 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2020; on this evidence the file is dormant.
The programme is broad: 9 distinct indication wordings are recorded for docetaxel by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 25 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess docetaxel, on 9 May 2003; PBAC (Australia) did not open a file until 2017 — an unusually long tail of 14.2 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 14 years in total.
4 of the 7 agencies here assessed docetaxel more than once, HAS (France) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for docetaxel.
The full ledger for docetaxel reads 11 recommended, 5 withdrawn, 3 not recommended and 3 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 24 Sep 2020 | Early breast cancer- contraindicated to anthracycline treatment | PTAC advice: High · decision reached | source |
| HAS (France) | 24 Jan 2018 | Other request | SMR insufficient | source |
| PBAC (Australia) | 2017 | Unrestricted | The PBAC noted the change to the listings processed by the secretariat. | source |
| AWMSG (Wales) | 17 Nov 2011 | Adjuvant treatment of patients with operable node-negative breast cancer in combination with doxorubicin and cyclophosph… | outside AWMSG criteria | source |
| SMC (Scotland) | 8 Nov 2010 | for the treatment of patients with operable node-negative breast cancer. | withdrawn | source |
20 further decisions for docetaxel, across 6 agencies, are not shown here. They link to 18 further source documents.
Related molecules
- paclitaxel — same ATC class L01C — Antineoplastics
- irinotecan — same ATC class L01C — Antineoplastics
- topotecan — same ATC class L01C — Antineoplastics
- trabectedin — same ATC class L01C — Antineoplastics
- cabazitaxel — same ATC class L01C — Antineoplastics
- vinorelbine — same ATC class L01C — Antineoplastics
Coverage: 25 decisions for docetaxel from 7 agencies, 2003 to 2020. Data to 7 Sep 2026. ATC class L01C — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.